NCT00098124

Study of Milnacipran for the Treatment of Fibromyalgia

A Phase III Pivotal, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Milnacipran for the Treatment of Fibromyalgia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,200 (planned)
• Sponsor: Forest Laboratories · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Antidepressants of all varieties represent a common form of therapy for many chronic states including fibromyalgia. The majority of antidepressants increase the levels of serotonin or norepinephrine in the central nervous system. Milnacipran is a dual norepinephrine and serotonin reuptake inhibitor and may be effective in the treatment of fibromyalgia.

Conditions

• Fibromyalgia

Interventions

Type	Name	Description
DRUG	milnacipran hydrochloride

Timeline

• Start date: 2004-11-01
• Completion: 2006-12-01
• First posted: 2004-12-06
• Last updated: 2007-12-24

Locations

80 sites across 1 country: United States